Profile data is unavailable for this security.
About the company
Stille AB is a Sweden-based company engaged in the development, manufacture, and marketing of technical medical equipment. The product portfolio is divided into two business lines. The Surgery business area develops, produces and markets handcrafted, forged surgical instruments for all fields of open surgery, with an emphasis on cardiovascular surgery, and reconstructive and aesthetic plastic surgery. Its products include scissors, forceps, artery forceps, needle holders and clamps, among others. The Patient Positioning area develops and manufactures two main groups of procedure-specific specialized tables for cardiovascular surgery and gynecology, urology and urodynamic examinations. As of December 31, 2011, the Company had two wholly owned subsidiaries, Stille Surgical Inc. and Stille Incentive AB. As of December 30, 2011, the it's largest shareholder was Linc Invest AB (39.81%). On September 2, 2013, the Company sold its business unit, Sonesta, to ADDvise Lab Solutions publ AB.
- Revenue in SEK (TTM)429.68m
- Net income in SEK47.88m
- Incorporated1984
- Employees143.00
- LocationStille ABEkbacken 11TORSHAELLA 644 30SwedenSWE
- Phone+46 858858000
- Fax+46 858858005
- Websitehttps://www.stille.se/
Mergers & acquisitions
Acquired company | STIL:STO since announced | Transaction value |
---|---|---|
Fehling Instruments Gmbh & Co. Kg | 96.19% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Optomed Oyj | 167.44m | -55.23m | 1.04bn | 110.00 | -- | 3.33 | -- | 6.20 | -0.2761 | -0.2761 | 0.8501 | 1.40 | 0.4762 | 1.69 | 4.10 | 129,035.10 | -15.71 | -12.95 | -19.11 | -15.90 | 67.77 | 65.69 | -32.98 | -27.84 | 2.67 | -- | 0.1424 | -- | 3.00 | 3.47 | 18.84 | -- | 7.26 | -- |
Paxman AB (publ) | 238.86m | 28.64m | 1.06bn | 102.00 | 37.12 | 7.27 | 22.60 | 4.44 | 1.50 | 1.50 | 12.54 | 7.67 | 1.31 | 2.74 | 6.56 | 2,624,791.00 | 15.66 | -5.08 | 20.74 | -7.76 | 70.27 | 69.38 | 11.99 | -5.07 | 1.98 | 12.73 | 0.0838 | -- | 43.99 | 29.35 | 180.69 | -- | 6.26 | -- |
BioPorto A/S | 51.65m | -76.36m | 1.21bn | 33.00 | -- | 7.54 | -- | 23.37 | -0.1397 | -0.1397 | 0.0941 | 0.244 | 0.2777 | 3.23 | 9.02 | 1,091,290.00 | -41.06 | -71.10 | -51.28 | -96.55 | 71.13 | 63.38 | -147.84 | -239.22 | 5.16 | -- | 0.0517 | -- | 6.87 | 3.54 | 25.81 | -- | -51.56 | -- |
ADDvise Group AB (publ) | 1.54bn | 137.40m | 1.25bn | 637.00 | 16.41 | 2.88 | 5.24 | 0.8088 | 0.7191 | 0.7191 | 8.07 | 4.10 | 0.5142 | 7.24 | 5.04 | 2,474,039.00 | 4.58 | 3.72 | 5.63 | 4.77 | 44.82 | 48.95 | 8.91 | 5.89 | 1.36 | 3.24 | 0.6913 | 0.9405 | 44.30 | 38.62 | 27.62 | -- | 30.35 | -- |
C Rad AB | 458.22m | 48.23m | 1.27bn | 89.00 | 26.95 | 4.47 | 22.04 | 2.76 | 1.43 | 1.43 | 13.57 | 8.61 | 1.20 | 4.90 | 3.05 | 5,266,839.00 | 12.69 | 5.09 | 17.96 | 7.02 | 45.14 | 43.12 | 10.61 | 4.86 | 2.43 | -- | 0.0058 | 0.00 | 40.92 | 17.44 | 375.05 | 10.89 | 33.69 | -- |
Bactiguard Holding AB | 230.51m | -76.04m | 1.55bn | 177.00 | -- | 5.31 | -- | 6.71 | -2.17 | -2.17 | 6.58 | 9.37 | 0.3266 | 3.61 | 7.52 | 1,062,240.00 | -10.77 | -7.56 | -14.93 | -8.81 | 43.80 | 47.91 | -32.99 | -26.28 | 0.5741 | -3.93 | 0.4215 | -- | -11.96 | 6.46 | -161.71 | -- | 8.43 | -- |
Nordhealth As | 469.40m | -106.06m | 1.58bn | 355.00 | -- | 3.12 | 95.75 | 3.38 | -1.40 | -1.40 | 6.16 | 11.56 | 0.4329 | -- | 6.73 | 1,221,097.00 | -9.78 | -- | -11.11 | -- | 85.82 | -- | -22.59 | -- | -- | -- | 0.00 | -- | 18.60 | -- | 21.96 | -- | -- | -- |
Genovis AB | 127.02m | 17.25m | 1.64bn | 37.00 | 94.88 | 7.88 | 56.31 | 12.88 | 0.2635 | 0.2635 | 1.94 | 3.17 | 0.4938 | -- | -- | 3,432,973.00 | 6.71 | 18.56 | 7.21 | 21.45 | 64.41 | 65.51 | 13.58 | 23.88 | -- | 697.00 | 0.2718 | 0.00 | 54.54 | 35.56 | 449.56 | -- | 47.59 | -- |
Stille AB | 429.68m | 47.88m | 1.90bn | 143.00 | 30.94 | 2.89 | 27.70 | 4.43 | 6.85 | 6.85 | 61.34 | 73.40 | 0.6219 | 1.97 | 8.16 | 4,053,557.00 | 6.93 | 7.03 | 8.32 | 8.19 | 47.97 | 43.93 | 11.14 | 9.85 | 1.07 | 11.55 | 0.00 | 21.98 | 19.70 | 16.78 | -2.48 | 5.34 | 23.62 | -- |
Sedana Medical AB (publ) | 168.68m | -41.47m | 2.31bn | 81.00 | -- | 2.38 | -- | 13.72 | -0.4175 | -0.4175 | 1.70 | 9.79 | 0.1609 | 1.19 | 10.82 | 2,135,139.00 | -3.95 | -5.77 | -4.17 | -6.08 | 70.32 | 64.06 | -24.59 | -36.13 | 5.66 | -- | 0.0081 | -- | 25.23 | 21.59 | 18.90 | -- | 42.12 | -- |
Holder | Shares | % Held |
---|---|---|
Healthinvest Partners ABas of 31 Aug 2023 | 460.00k | 5.12% |
Lannebo Fonder ABas of 31 Aug 2023 | 445.88k | 4.96% |
SEB Investment Management ABas of 31 Aug 2023 | 392.20k | 4.37% |
Aktia Bank Plc (Investment Management)as of 31 Jul 2024 | 380.35k | 4.23% |
Aktia Fondbolag Abas of 31 Aug 2023 | 220.00k | 2.45% |
Fondita Fund Management Co. Ltd.as of 30 Jun 2024 | 180.00k | 2.00% |
ODIN Forvaltning AS (Sweden)as of 28 Jun 2024 | 67.00k | 0.75% |
Schroder Investment Management Ltd.as of 31 Dec 2023 | 60.00k | 0.67% |
Amundi Asset Management SA (Investment Management)as of 28 Jun 2024 | 35.64k | 0.40% |
HC Capital Advisors GmbHas of 31 Dec 2023 | 20.00k | 0.22% |